Curis, Inc. — FY2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report. Curis is a clinical-stage biotechnology company developing cancer therapeutics; Erivedge royalties were its only material revenue source.
Financial performance and position
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue, net | $10.6 million | $10.8 million | Down 2% |
| Operating loss | $42.1 million | $24.9 million | Loss increased |
| Net loss | $45.4 million | $29.9 million | Loss increased 52% |
| Net loss per share | $0.50 | $0.61 | Loss per share decreased |
| Net cash used in operations | $37.6 million | $25.7 million | Cash use increased |
- Royalties were $10.7 million; Genentech accounted for 100% of FY2021 gross revenue. Revenue remained highly dependent on Erivedge sales and related royalty terms.
- Research and development expense rose 51% to $34.9 million, primarily from higher clinical, manufacturing, personnel, and stock-compensation costs. General and administrative expense rose 43% to $17.3 million.
- Cash, cash equivalents, and investments totaled $139.8 million at year-end, including $40.0 million in cash and cash equivalents and $99.8 million in investments. Current assets were $122.4 million and current liabilities $13.4 million.
- The company reported no long-term debt at year-end. It had a $53.8 million liability related to the sale of future Erivedge royalties to Oberland. The filing reports no Oberland event of default as of December 31, 2021.
- Total assets were $162.3 million and stockholders’ equity was $90.7 million at year-end, compared with $204.4 million and $130.7 million, respectively, at December 31, 2020.
Business, developments, and comparison with prior year
- Curis’s principal development priorities were emavusertib (CA-4948), an IRAK4 inhibitor, and CI-8993, a VISTA-targeting antibody. Both were in early-stage clinical development.
- Emavusertib was being studied in Phase 1/2 trials for lymphoma and relapsed/refractory AML and high-risk MDS, with combination cohorts also underway. The FDA granted it Orphan Drug Designation for AML and MDS in April 2021.
- CI-8993 was in a Phase 1 trial for relapsed/refractory solid tumors. Curis held an option to license it from ImmuNext; exercising the option would require a $20.0 million fee, in addition to potential milestone and royalty obligations.
- Fimepinostat’s venetoclax combination study and the CA-170 mesothelioma study were not continuing to enroll patients after insufficient efficacy signals. CA-170 remained subject to a separate Aurigene-funded study plan.
- Compared with FY2020, revenue was broadly stable, while R&D and G&A spending and operating cash use increased substantially. Net loss widened; reported loss per share narrowed from $0.61 to $0.50, alongside a higher weighted-average share count following 2020 equity financings.
Outlook, risks, and unusual items
- Management estimated that year-end cash, cash equivalents, and investments would fund planned operations into 2024, subject to assumptions that may prove inaccurate. The filing states Curis expects continued operating losses and does not expect profitability in the foreseeable future.
- Management expected near-term success to depend on clinical progress and favorable data for emavusertib and CI-8993, and on the ability to raise additional financing. The filing cited expected initial data from the emavusertib–ibrutinib combination study in the first half of 2022; subsequent clinical updates described in the filing are preliminary.
- COVID-19-related site restrictions, recruitment challenges, supply-chain disruption, and potential impacts on Erivedge prescriptions could delay trials and affect royalty receipts. Curis also relies on third parties for clinical trials, manufacturing, and commercialization.
- Funding and dilution remain material risks: Curis reported a $1.1 billion accumulated deficit and may need substantial additional capital. It had an unused $100 million at-the-market sales agreement and $21.6 million remaining under its Aspire Capital purchase agreement, both subject to market conditions and other limitations.
- Erivedge royalties are exposed to competing products and contractual reductions. Under the Oberland agreement, royalty allocations are shared, and a default could permit the purchaser to redirect payments and require a repurchase at a contractually defined price.
- FY2021 included a $0.9 million gain from full forgiveness of the PPP loan. Other expense included $4.5 million of imputed interest related to the future-royalty liability. The independent auditor identified valuation of that liability as a critical audit matter, citing significant management estimates of future Erivedge royalties.
- The company’s financial statements received an unqualified audit opinion; management and the auditor reported effective internal control over financial reporting as of year-end.
Important facts for investors to verify
- Current clinical-trial enrollment, safety, efficacy, and timelines for emavusertib and CI-8993, distinguishing preliminary updates from complete, audited study results.
- Whether the $139.8 million liquidity balance and stated runway into 2024 remain adequate as trial, manufacturing, and other costs evolve.
- Erivedge sales and royalty receipts, the allocation of those receipts under the Oberland agreement, and the assumptions used to value the $53.8 million royalty liability.
- Potential future dilution from equity facilities and the substantial milestone, option-exercise, and royalty obligations under the Aurigene and ImmuNext agreements.
- The extent to which COVID-19, competition, and dependence on Genentech and Roche affect trial execution and the company’s concentrated revenue stream.